Abstract
Background: Insulin increases glucose uptake in muscles and fat and inhibits hepatic glucose production, thus serving as the primary regulator of the blood glucose level. In type 2 diabetes, insufficient insulin release and suppressed insulin action [named insulin resistance] lead to increased glucose production in liver and decreased glucose uptake by muscles and fat tissues, resulting in elevated blood glucose concentration which is dangerous to human health. Therefore, the anti-diabetic therapies are aimed at inhibiting excess blood glucose.
Methods: A comparative analysis of two distinct glucose-lowering modes was used to develop a new feedback model for the purpose of identification of pharmacological targets in diabetes treatment.
Results: The current brief opinion proposes an original feedback control of glucose-lowering regulation and its models which allow comparing two distinct strategies of glucose level correction, i.e., one of them allows reducing the increased threshold of insulin resistance, whereas the other allows overcoming this threshold/barrier using exogenous insulin treatment. Also, this analytic research presents selected examples comparing the influence of the two analyzed strategies on the normalization of glucose metabolism, their therapeutic potential and side effects associated with additional weight gain. These models show the pathological mechanism by which exogenous insulin provokes formation of a «vicious cycle» by its side effects associated with additional weight gain.
Conclusion: The presented model and findings can contribute to the development of new anti-diabetic targets and drugs with minimal side effects.
Keywords: Chronic low-grade inflammation, diabetes, insulin resistance, metabolism, side effects, vicious cycle, weigh gain.
Current Pharmaceutical Design
Title:Glucose-lowering Strategies in Diabetes: Pharmacological Development of New Antidiabetic Drugs
Volume: 24 Issue: 9
Author(s): Polina Schwartsburd*
Affiliation:
- Institute of Theoretical and Experimental Biophysics, Russian Academy of Sciences, Institutskay ulitsa 3, Pushchino, Moscow Region, 142290,Russian Federation
Keywords: Chronic low-grade inflammation, diabetes, insulin resistance, metabolism, side effects, vicious cycle, weigh gain.
Abstract: Background: Insulin increases glucose uptake in muscles and fat and inhibits hepatic glucose production, thus serving as the primary regulator of the blood glucose level. In type 2 diabetes, insufficient insulin release and suppressed insulin action [named insulin resistance] lead to increased glucose production in liver and decreased glucose uptake by muscles and fat tissues, resulting in elevated blood glucose concentration which is dangerous to human health. Therefore, the anti-diabetic therapies are aimed at inhibiting excess blood glucose.
Methods: A comparative analysis of two distinct glucose-lowering modes was used to develop a new feedback model for the purpose of identification of pharmacological targets in diabetes treatment.
Results: The current brief opinion proposes an original feedback control of glucose-lowering regulation and its models which allow comparing two distinct strategies of glucose level correction, i.e., one of them allows reducing the increased threshold of insulin resistance, whereas the other allows overcoming this threshold/barrier using exogenous insulin treatment. Also, this analytic research presents selected examples comparing the influence of the two analyzed strategies on the normalization of glucose metabolism, their therapeutic potential and side effects associated with additional weight gain. These models show the pathological mechanism by which exogenous insulin provokes formation of a «vicious cycle» by its side effects associated with additional weight gain.
Conclusion: The presented model and findings can contribute to the development of new anti-diabetic targets and drugs with minimal side effects.
Export Options
About this article
Cite this article as:
Schwartsburd Polina *, Glucose-lowering Strategies in Diabetes: Pharmacological Development of New Antidiabetic Drugs, Current Pharmaceutical Design 2018; 24 (9) . https://dx.doi.org/10.2174/1381612824666171227222113
DOI https://dx.doi.org/10.2174/1381612824666171227222113 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pleiotropic Effects of Nicotinic Acid: Beyond High Density Lipoprotein Cholesterol Elevation
Current Vascular Pharmacology Fatty Acids: Friends or Foe? Relation Between Dietary Fat and Insulin Sensitivity
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Animal Models of Diabetes Mellitus: Relevance to Vascular Complications
Current Pharmaceutical Design Depression and its Relation with Uncontrolled Hypertension and Increased Cardiovascular Risk
Current Hypertension Reviews Perceptions in Type 1 Diabetes Mellitus with or Without the Use of Insulin Pump: An Online Study
Current Diabetes Reviews Correlations between Insomnia and Sex, Work Experience, Shift and Body Max Index in Italian Nurses: A Scoping Profile Statement
Endocrine, Metabolic & Immune Disorders - Drug Targets Oxidative Stress and Endothelial Function: Therapeutic Interventions
Recent Patents on Cardiovascular Drug Discovery The Application of Metabolomic Profiling to the Effects of Physical Activity
Current Metabolomics Plasma VEGF and IL-8 Levels in Patients with Mixed Dyslipidaemia. Effect of Rosuvastatin Monotherapy or its Combination at a Lower Dose with Omega-3 Fatty Acids: A Pilot Study
Current Vascular Pharmacology Polymer-Based Drug Delivery Devices for Neurological Disorders
CNS & Neurological Disorders - Drug Targets Immune Status 'in Children with Beta Thalassemia' in Correlation 'with Iron Overload': Single Center Egyptian Study
Endocrine, Metabolic & Immune Disorders - Drug Targets Sodium-glucose Cotransporter 2 Inhibitors: Glucose Lowering Against other Hypoglycemic Agents
Cardiovascular & Hematological Disorders-Drug Targets Survey of Functional Activities of Alpha-fetoprotein Derived Growth Inhibitory Peptides: Review and Prospects
Current Protein & Peptide Science Controversies of Androgen Ablation Therapy for Metastatic Prostate Cancer
Current Pharmaceutical Design Expression of Rab3b in Human Glioma: Influence on Cell Proliferation and Apoptosis
Current Pharmaceutical Design Chronic Inflammation in the Pancreas and Salivary Glands - Lessons from Similarities and Differences in Pathophysiology and Treatment Modalities
Current Pharmaceutical Design Prospects and Limitations of T Cell Receptor Gene Therapy
Current Gene Therapy Neuroinflammation, Oxidative Stress and the Pathogenesis of Alzheimers Disease
Current Pharmaceutical Design Obesity in the Cardiovascular Continuum
Current Clinical Pharmacology The Effect of SEX/Gender on Cardiovascular Pharmacology
Current Pharmaceutical Design